Concepedia

Author

Meg Annan

GlaxoSmithKline (United States)

Also Known As

Meg Annan

5

Publications

428

Citations

4

H-Index

25

Concepts

All Affiliations

GlaxoSmithKline (United States)Harvard UniversityThe University of Texas MD Anderson Cancer CenterBrigham and Women's HospitalUniversity of Pennsylvania
MA

About

Meg Annan is an author at GlaxoSmithKline (United States) specializing in medicine, pharmacology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

217

2

Engineering

1

1

180

3

Biomedical Engineering

1

1

180

4

Cell Biology

1

1

37

5

Electrical Engineering

1

1

180

Meg Annan

×

4

Publications

424

Citations

4

H-Index

YearCitations

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

Sarina A. Piha‐Paul, Christine L. Hann, Christopher A. French,

JNCI Cancer Spectrum

2019

196

Reduction of Signal Suppression Effects in ESI-MS Using a Nanosplitting Device

Eric T. Gangl, Meg Annan, Neil Spooner,

Analytical Chemistry

2001

180

Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers

Peter J. O’Dwyer, Sarina A. Piha‐Paul, Christopher A. French,

Cancer Research

2016

37

Trimethylsilyl group migration in the mass spectra of trimethylsilyl ethers of cholesterol oxidation products. product ion characterization by linked-scan tandem mass spectrometry

Meg Annan, P.W. Lequesne, Paul Vouros

Journal of the American Society for Mass Spectrometry

1993

11

Page 1